Study Title
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma (NCT01569204)
Trial Description
The purpose of this clinical trial is to determine the complete response rate (CRR) after six cycles of chemotherapy, as well as to determine the complete remission rate (CR/CRr) as final treatment outcome after completion of treatment. In this trial, the BEACOPP Variant is a chemotherapy regimen consisting of etoposide, cyclophosphamide, doxorubicin hydrochloride, prednisone, procarbazine, dexamethasone, dacarbazine and brentuximab vedotin, used for the treatment of advanced-stage Hodgkin lymphoma (HL).
This trial is sponsored by University of Cologne. [1]
Study Data
- Condition: Hodgkin Lymphoma
- Interventions:
- Drugs used in this trial
- Etoposide (Toposar®; Pfitzer, Inc.)
- Cyclophosphamide (Cytoxan® ;Bristol-Myers Squibb Company
- Doxorubicin (Adriamycin®; Pfizer)
- Prednisolone (Orapred®; Concordia Healthcare Corp.)
- Procarbazine (Matulane®; Sigma-Tau Pharmaceuticals)
- Dexamethasone (Decadron®*/IntensolTM; Boehringer-Ingelheim/Roxanne Laboratories)
- Dacarbazine (DTIC-Dome®; Bayer Pharmaceuticals Corporation)
- Brentuximab Vedotin (Adcetris®; Seattle Genetics, Inc.)
- Drugs used in this trial
- Phase: II
- Estimated Enrollment: 100
- Start: October 2012
- Estimated Completion: December 2015
- Last verified: December 2014
Click here for an overview of other trials with brentuximab vedotion.
Study Schematic
Click here to Return to Drug map
Last Editorial review: July 20, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
* While generic versions of this drug are still available, this Brand Name drug is no longer available in the United States.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
